Read by QxMD icon Read

Prostate cancer bone scan frequency

Danil V Makarov, Elaine Y C Hu, Dawn Walter, R Scott Braithwaite, Scott Sherman, Heather T Gold, Xiao-Hua Andrew Zhou, Cary P Gross, Steven B Zeliadt
OBJECTIVE: To determine the frequency of appropriate and inappropriate prostate cancer imaging in an integrated health care system. DATA SOURCES/STUDY SETTING: Veterans Health Administration Central Cancer Registry linked to VA electronic medical records and Medicare claims (2004-2008). STUDY DESIGN: We performed a retrospective cohort study of VA patients diagnosed with prostate cancer (N = 45,084). Imaging (CT, MRI, bone scan, PET) use was assessed among patients with low-risk disease, for whom guidelines recommend against advanced imaging, and among high-risk patients for whom guidelines recommend it...
June 2016: Health Services Research
Mitsuru Koizumi, Noriaki Miyaji, Taisuke Murata, Kazuki Motegi, Kenta Miwa, Masamichi Koyama, Takashi Terauchi, Kei Wagatsuma, Kazunori Kawakami, Jens Richter
OBJECTIVE: BONENAVI is a computer-assisted diagnosis system that analyzes bone scintigraphy automatically. We experienced more than a few segmentation errors with the previous BONENAVI version (2.0.5). We have since obtained a revised version (2.1.7) and evaluate it. METHODS: Bone scans of patients were analyzed by BONENAVI version 2.0.5 and a revised version 2.1.7 with regard to segmentation errors, sensitivity, and specificity. Patients with skeletal metastases from prostate cancer, lung cancer, breast cancer, and other cancers were included in the study as true-positive cases...
October 2015: Annals of Nuclear Medicine
Ahmed A Hussein, Sanoj Punnen, Shoujun Zhao, Janet E Cowan, Michael Leapman, Thanh C Tran, Samuel L Washington, Matthew D Truesdale, Peter R Carroll, Matthew R Cooperberg
PURPOSE: Data are limited on imaging after primary treatment of localized prostate cancer. MATERIALS AND METHODS: We identified 8,435 men newly diagnosed with nonmetastatic prostate cancer in 1995 to 2012 who were enrolled in CaPSURE™. Patients were followed after primary treatment with radical prostatectomy, cryosurgery, brachytherapy, external beam radiation therapy or androgen deprivation therapy. We assessed the use of bone scan, computerized tomography and magnetic resonance imaging after primary treatment...
July 2015: Journal of Urology
A N Damji, K Bies, S M H Alibhai, J M Jones
UNLABELLED: The study determined prostate cancer specialists' knowledge and concordance to guidelines regarding the diagnosis, management, and prevention of androgen deprivation therapy-induced osteoporosis. Despite high knowledge regarding bone health, most respondents did not routinely measure bone mineral density or use fracture risk assessment tools, suggesting a significant gap in the screening/monitoring of bone health. INTRODUCTION: The purpose of this study was to determine prostate cancer specialists' knowledge, practices, self-perceived competencies and barriers to providing guideline-concordant care in the diagnosis, prevention, and management of androgen deprivation therapy (ADT)-induced osteoporosis (OP)...
March 2015: Osteoporosis International
Debasish Sundi, Jason E Cohen, Alexander P Cole, Brian P Neuman, John Cooper, Farzana A Faisal, Ashley E Ross, Edward M Schaeffer
BACKGROUND: The use of multidisciplinary clinics (MDCs) for outpatient cancer evaluation is increasing. MDCs may vary in format, and data on whether MDCs change prostate cancer (PCa) care are limited. Here we report on the setup and design of a relatively new PCa MDC clinic. Because MDC evaluation was associated with a comprehensive re-evaluation of all patients' staging and risk stratification data, we studied the frequency of changes in PCa grade and stage upon MDC evaluation, which provides a unique estimate of the magnitude of pathology, radiology, and exam-based risk stratification in a modern tertiary setting...
February 2015: Prostate
E David Crawford, Nelson N Stone, Evan Y Yu, Phillip J Koo, Stephen J Freedland, Susan F Slovin, Leonard G Gomella, E Roy Berger, Thomas E Keane, Paul Sieber, Neal D Shore, Daniel P Petrylak
Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A multidisciplinary group was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. The aim of this review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer...
March 2014: Urology
A Heidenreich, S Krege
BACKGROUND: Imaging studies are an integral and important diagnostic modality to stage, monitor, and follow-up patients with metastatic urogenital cancer. The currently available guidelines on diagnosis and treatment of urogenital cancer do not provide the clinician with evidence-based recommendations for daily routine. It is the aim of the current manuscript to develop scientifically valid recommendations with regard to the most appropriate imaging technique and the most useful time interval in metastatic urogenital cancer patients undergoing systemic therapy...
November 2013: Der Urologe. Ausg. A
P Gélat, G Ter Haar, N Saffari
High intensity focused ultrasound (HIFU) enables highly localized, non-invasive tissue ablation and its efficacy has been demonstrated in the treatment of a range of cancers, including those of the kidney, prostate and breast. HIFU offers the ability to treat deep-seated tumours locally, and potentially bears fewer side effects than more invasive treatment modalities such as resection, chemotherapy and ionizing radiation. There remains however a number of significant challenges which currently hinder its widespread clinical application...
December 21, 2012: Physics in Medicine and Biology
Charles J Ryan, Shreya Shah, Eleni Efstathiou, Matthew R Smith, Mary-Ellen Taplin, Glenn J Bubley, Christopher J Logothetis, Thian Kheoh, Christine Kilian, Christopher M Haqq, Arturo Molina, Eric J Small
PURPOSE: Abiraterone is an oral inhibitor of CYP17, which is essential for androgen biosynthesis. This multicenter study assessed its efficacy in patients with castration-resistant prostate cancer (CRPC), without prior chemotherapy or CYP17-targeted therapy, and frequency of bone scans discordant with prostate-specific antigen (PSA) and clinical response. EXPERIMENTAL DESIGN: Thirty-three patients received abiraterone acetate 1,000 mg daily with prednisone 5 mg twice daily in continuous 28-day cycles...
July 15, 2011: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Roberto Molina Escudero, Felipe Herranz Amo, M C Navas Martínez, Juan Tabares Jiménez, A Husillos Alonso, G Ogaya Piniés, Carlos Hernández Fernández
OBJECTIVE: To review the unusual localizations of metastasic prostate cancer with the contribution of a clinical case of prostatic adenocarcinoma metastasis in the thyroid cartilage. METHODS: 49-year-old-male admitted with history of 48 hour hematuria associated with lumbar pain radiating to the lower extremities and cervical tumour for 3 months. RESULTS: CT scan of the thorax, abdomen and pelvis was performed showing an insufflating lesion on the left thyroid cartilage lamina suggesting chondrosarcoma, a 4 cm tumour on the posterior side of the bladder, and metastases on L4-S1 vertebral bodies and left iliac bone...
March 2011: Archivos Españoles de Urología
Gary J R Cook, Ram Venkitaraman, Aslam S Sohaib, Valerie J Lewington, Sue C Chua, Robert A Huddart, Christopher C Parker, David D Dearnaley, Alan Horwich
PURPOSE: Bone scintigraphy (BS) lacks sensitivity for detecting very early skeletal metastases (SM) in prostate cancer (PC) and is often limited by poor specificity. Also scintigraphic flare of SM can occur following effective treatment and mislead an early response assessment. We hypothesised that a flare reaction might amplify the signal from subclinical SM, increasing the sensitivity of BS and that the phenomenon may be specific for metastases. METHODS: We conducted a prospective study to determine the frequency of the flare phenomenon in patients with metastatic PC starting hormone therapy and to explore its utility in patients with negative staging scans but considered at high risk of SM and in those with equivocal baseline BS abnormalities...
January 2011: European Journal of Nuclear Medicine and Molecular Imaging
Spiros G Pneumaticos, Sofia N Chatziioannou, Christiana Savvidou, Anastasia Pilichou, Dimitra Rontogianni, Dimitrios S Korres
Vertebral augmentation procedures are currently widely performed to treat vertebral compression fractures. The purpose of this study was to determine the frequency of underlying previously unrecognized etiology in a consecutive series of patients undergoing kyphoplasty to treat vertebral compression fractures. A prospective histological evaluation of vertebral body biopsy specimens from presumed osteoporotic vertebral compression fractures were performed in order to identify aforementioned causes. Over a 2-year period, vertebral body biopsies from 154 vertebral levels were performed in 75 patients undergoing kyphoplasty for vertebral compression fractures...
November 2010: European Spine Journal
Howard I Scher, Susan Halabi, Ian Tannock, Michael Morris, Cora N Sternberg, Michael A Carducci, Mario A Eisenberger, Celestia Higano, Glenn J Bubley, Robert Dreicer, Daniel Petrylak, Philip Kantoff, Ethan Basch, William Kevin Kelly, William D Figg, Eric J Small, Tomasz M Beer, George Wilding, Alison Martin, Maha Hussain
PURPOSE: To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS: A committee of investigators experienced in conducting trials for prostate cancer defined new consensus criteria by reviewing previous criteria, Response Evaluation Criteria in Solid Tumors (RECIST), and emerging trial data. RESULTS: The Prostate Cancer Clinical Trials Working Group (PCWG2) recommends a two-objective paradigm: (1) controlling, relieving, or eliminating disease manifestations that are present when treatment is initiated and (2) preventing or delaying disease manifestations expected to occur...
March 1, 2008: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Małgorzata Benke, Grazyna Lapińska, Joanna Niewiadomska, Anna Garszel, Grzegorz Benke, Izabella Kozłowicz-Gudzińska
Bone scan remains the most frequently requested investigation in any nuclear medicine department. The main reason for this is the exquisite sensivity of the bone scan for lesion detection, combined with clear visualisation of the whole skeleton. The isotope bone scan is now generally accepted as initial investigation of choice in the search for bone metastases from most tumours. 13583 bone scans for metastases were performed in our institution in 1998-2002 years. The frequency of bone metastases was highest in breast, prostate and lung cancer (53,9%, 58,6% and 29,5% respectively)...
April 30, 2003: Ortopedia, Traumatologia, Rehabilitacja
Susan F Slovin
BACKGROUND: A 52-year-old man presented to his urologist with hematuria and symptoms of frequency and incomplete voiding. The patient received antibiotics without symptom resolution. His prostate-specific antigen (PSA) level was 6.6 ng/ml and digital rectal examination revealed a normal-sized firm prostate gland. Biopsy obtained by transurethral resection revealed poorly differentiated Gleason 9 adenocarcinoma of the prostate with small-cell/neuroendocrine features. Pure small-cell cancer or poorly differentiated prostate cancer may secrete little or no PSA...
September 2007: Nature Clinical Practice. Oncology
Roger Kirby
BACKGROUND: A 60-year-old man, with a 2-year history of lower-urinary-tract symptoms (frequency and reduced flow) and perineal discomfort, presented with a serum PSA level of 42 ng/ml. INVESTIGATIONS: Digital rectal examination, transrectal ultrasound, prostate biopsy (8 cores), prostate and pelvic MRI, renal ultrasound and bone scan. DIAGNOSIS: cT3b, N0, M0 prostate cancer (Gleason score 7 [4 + 3]). MANAGEMENT: Hormonal down-staging with bicalutamide 150 mg/day for 3 months, then conformal radiotherapy (70 Gy over 7 weeks) with adjuvant bicalutamide 150 mg/day, to be continued until disease progression...
June 2005: Nature Clinical Practice. Urology
V Rusu, L V Boiculese, Cipriana Stefănescu, D Hountis, Mihaela Costin
UNLABELLED: 420 patients with cancer of breast, prostate, lung and colon were investigated through 99mTc Methylene-diphosphonate whole body scintigraphy. The presence of pathologic radiotracer uptake was qualitatively and quantitatively analyzed in order to establish the metastases distribution. Patient selection was realized over 2455 whole body scintigraphies effectuated between 1998 and 2001 in our Nuclear Medicine Service. All selected cases were metastases with known origin primary cancer...
January 2004: Revista Medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti Din Iaş̧i
Ralf Herwig, Wolfgang Horninger, Peter Rehder, Helmut Klocker, Reinhold Ramoner, Martin Thurnher, Germar M Pinggera, Christian Gozzi, Günther Konwalinka, Georg Bartsch
BACKGROUND: Prostate-specific antigen (PSA) is a widely used serum marker for prostate cancer, but has a poor specificity for early detection at levels below 10 ng/ml, because it can also result from benign conditions. Our aim was to determine the frequencies of circulating PSA+ macrophages in a blinded study and to examine the suitability of this new method for differentiating between benign and malignant prostate disease. METHODS: Between October 2002 and February 2003, 126 patients undergoing transrectal biopsy were enrolled in this study...
February 15, 2005: Prostate
Dennis A Faith, William B Isaacs, James D Morgan, Helen L Fedor, Jessica L Hicks, Leslie A Mangold, Patrick C Walsh, Alan W Partin, Elizabeth A Platz, Jun Luo, Angelo M De Marzo
BACKGROUND: Human intestinal trefoil factor 3 (TFF3) is a member of a family of polypeptides encoded by a cluster of genes on chromosome 21. Through gene expression profiling studies TFF3 mRNA has been found to be overexpressed in prostate cancer. METHODS: We used immunochemistry on tissue microarrays and software tools, collectively referred to as TMAJ, for online assessment of staining to analyze samples from 294 primary tumors and 61 metastatic lesions. RESULTS: Applying a cutoff of 20% of cells staining as positive, the frequency of staining was 18...
November 1, 2004: Prostate
J J Body, I Mancini
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, and it is well accepted that tumor cells in bone, especially breast cancer and myeloma cells, can stimulate osteoclast formation and activity leading to the release of growth factors or cytokines, which will further stimulate cancer cells' growth and their secretion of osteolytic factors. BPs are now the standard treatment for cancer hypercalcemia, for which a dose of 90 mg of pamidronate or 1500 mg of clodronate is recommended; the former compound is more potent and has a longer lasting effect...
July 2002: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"